Despite the availability of safe and effective endoscopic treatment of Barrett's esophagus (BE)-related dysplasia and neoplasia, the incidence and mortality from esophageal adenocarcinoma (EAC) have continued to increase. This likely stems from the large population of patients that develop EAC outside of a BE screening and surveillance program. Identification of BE with screening followed by enrollment in an appropriate surveillance/risk stratification program could be a strategy to address both the incidence of and mortality from EAC. This article summarizes the rationale and challenges for BE screening, the risk factors for BE, and the currently described BE risk assessment tools.
|Original language||English (US)|
|Journal||Gastrointestinal Endoscopy Clinics of North America|
|State||Accepted/In press - 2017|
- Barrett's esophagus
- Esophageal adenocarcinoma
ASJC Scopus subject areas